Harbour Investments Inc. Has $159,000 Holdings in Theratechnologies Inc. (NASDAQ:THTX)

Harbour Investments Inc. increased its stake in shares of Theratechnologies Inc. (NASDAQ:THTX) by 20.0% during the fourth quarter, HoldingsChannel.com reports. The fund owned 87,772 shares of the company’s stock after purchasing an additional 14,655 shares during the period. Harbour Investments Inc.’s holdings in Theratechnologies were worth $159,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in THTX. National Bank of Canada FI lifted its holdings in Theratechnologies by 29.4% in the 3rd quarter. National Bank of Canada FI now owns 186,815 shares of the company’s stock worth $232,000 after purchasing an additional 42,435 shares during the last quarter. Wealthspire Advisors LLC raised its position in shares of Theratechnologies by 39.0% in the fourth quarter. Wealthspire Advisors LLC now owns 71,250 shares of the company’s stock valued at $129,000 after purchasing an additional 20,000 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in shares of Theratechnologies in the fourth quarter worth $27,000.

Analysts Set New Price Targets

Separately, Research Capitl upgraded shares of Theratechnologies to a “strong-buy” rating in a research note on Friday, February 14th.

Theratechnologies Stock Performance

Shares of NASDAQ:THTX opened at $1.58 on Friday. The stock’s 50-day moving average is $1.65 and its 200-day moving average is $1.48. The company has a market cap of $72.65 million, a P/E ratio of -15.80 and a beta of 1.24. Theratechnologies Inc. has a 52-week low of $1.08 and a 52-week high of $2.18.

Theratechnologies Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.